Inflammatory bowel diseases (IBD) is a collective term for mainly Crohn's disease and ulcerative colitis. The diseases often debuts at a young age and cause chronic or relapsing inflammation in the lining of the gastrointestinal tract throughout life. IBD generally has a high prevalence in Norway compared to many other countries. Causes and disease mechanisms are still poorly understood, and a major problem in both clinical practice and research is the unpredictable activity and course of the disease and the treatment effects. This often means a lifelong burden for the individual patient, the health service and the society.

The Gemini Centre is a model for strategic cooperation between research groups at NTNU, St. Olav’s University Hospital, SINTEF Industry and University of Oslo/Ullevål Oslo University Hospital. The partners in InTRaCC have complementary skills and resources related to individualized treatment and IBD. The aim is to combine our strengths to be able to carry out more extensive projects that can move research forward and contribute to precision medicine for these patients.